Lung (& tracheal) cancer, malignant (ICD10 C33-C34): combined sexes
One-year relative survival by HSE area of residence and age at diagnosis (2003-2007 diagnosis period)
|
One-year relative survival (with 95% confidence interval) by HSE area of residence (2003-2007) |
|||||||||||
|
Age at diagnosis |
Total |
Dublin / |
Dublin / |
South |
West |
||||||
|
|
Mid Leinster |
North East |
|||||||||
|
|
|||||||||||
|
all 15-99 |
29.9% |
31.3% |
30.2% |
29.2% |
28.5% |
||||||
|
(unstandardized) |
(28.8-30.9%) |
(29.4-33.2%) |
(28.1-32.3%) |
(27.2-31.2%) |
(26.4-30.5%) |
||||||
|
|
|||||||||||
|
all 15-99 |
32.0% |
33.6% |
32.3% |
31.1% |
31.1% |
||||||
|
(age-standardized)# |
(29.5-34.4%) |
(28.9-38.0%) |
(27.2-37.2%) |
(26.1-35.9%) |
(26.0-35.9%) |
||||||
|
|
|||||||||||
|
15-44 |
56.3% |
60.5% |
60.1% |
48.8% |
55.1% |
||||||
|
(48.4-63.3%) |
(44.3-73.3%) |
(44.3-72.6%) |
(32.9-62.9%) |
(38.5-68.8%) |
|||||||
|
|
|||||||||||
|
45-54 |
42.6% |
40.1% |
41.8% |
43.1% |
46.4% |
||||||
|
(38.7-46.3%) |
(33.4-46.6%) |
(33.6-49.7%) |
(35.2-50.7%) |
(38.1-54.2%) |
|||||||
|
|
|||||||||||
|
55-64 |
37.5% |
41.4% |
39.4% |
33.1% |
35.4% |
||||||
|
(35.2-39.6%) |
(37.1-45.5%) |
(34.8-43.9%) |
(29.0-37.3%) |
(30.7-40.0%) |
|||||||
|
|
|||||||||||
|
65-74 |
29.6% |
33.0% |
26.3% |
30.5% |
27.9% |
||||||
|
(27.8-31.3%) |
(29.7-36.3%) |
(22.8-29.7%) |
(26.9-34.1%) |
(24.5-31.3%) |
|||||||
|
|
|||||||||||
|
75-99 |
19.9% |
18.7% |
22.1% |
20.8% |
18.6% |
||||||
|
(18.4-21.5%) |
(15.9-21.5%) |
(18.7-25.6%) |
(17.7-23.9%) |
(15.6-21.8%) |
|||||||
Five-year relative survival by HSE area of residence and age at diagnosis (2003-2007 diagnosis period)
|
Five-year relative survival (with 95% confidence interval) by HSE area of residence (2003-2007) |
|||||||||||
|
Age at diagnosis |
Total |
Dublin / |
Dublin / |
South |
West |
||||||
|
|
Mid Leinster |
North East |
|||||||||
|
|
|||||||||||
|
all 15-99 |
11.7% |
13.3% |
12.7% |
8.8% |
12.2% |
||||||
|
(unstandardized) |
(10.7-12.7%) |
(11.4-15.2%) |
(10.7-14.7%) |
(7.1-10.6%) |
(10.2-14.3%) |
||||||
|
|
|||||||||||
|
all 15-99 |
12.7% |
13.8% |
13.6% |
9.9% |
13.4% |
||||||
|
(age-standardized)# |
(10.5-15.2%) |
(9.6-18.8%) |
(9.1-18.9%) |
(6.0-14.7%) |
(9.0-18.4%) |
||||||
|
|
|||||||||||
|
15-44 |
32.5% |
30.3% |
33.1% |
30.5% |
34.3% |
||||||
|
(24.5-40.7%) |
(15.1-47.0%) |
(16.2-51.2%) |
(17.0-45.1%) |
(20.0-49.1%) |
|||||||
|
|
|||||||||||
|
45-54 |
17.8% |
18.5% |
16.4% |
17.2% |
18.7% |
||||||
|
(14.5-21.4%) |
(12.5-25.3%) |
(10.4-23.7%) |
(10.7-25.0%) |
(12.2-26.4%) |
|||||||
|
|
|||||||||||
|
55-64 |
12.9% |
13.2% |
15.3% |
9.9% |
13.9% |
||||||
|
(10.9-14.9%) |
(9.6-17.4%) |
(11.5-19.6%) |
(6.8-13.7%) |
(9.92-18.4%) |
|||||||
|
|
|||||||||||
|
65-74 |
10.9% |
15.4% |
9.9% |
6.7% |
10.3% |
||||||
|
(9.4-12.5%) |
(12.3-18.8%) |
(7.2-12.9%) |
(4.1-10.1%) |
(7.2-13.9%) |
|||||||
|
|
|||||||||||
|
75-99 |
7.6% |
6.8% |
10.2% |
5.0% |
8.8% |
||||||
|
(6.1-9.4%) |
(4.2-10.3%) |
(6.7-14.5%) |
(2.7-8.4%) |
(6.1-12.3%) |
|||||||
|
Footnotes: |
|
|
# Age-standardized figures (presented for the more common cancers) use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000) |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|